Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2013 | short review

Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

verfasst von: Spyridon Dimitrios Chondropoulos, MD, Annaliza Delastic, MD, Alexandros Spyridonidis, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

In the past years, new emerging targeted therapies against specific markers have revolutionized the field of treating malignancies. In this article, we discuss the first available agent that targets a specific molecule in acute myeloid leukemia, as well as the future possibilities that genetic research unveil.
Vorheriger Artikel T-DM1 in breast cancer therapeutics: the first drug of its generation
Nächster Artikel Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas
Literatur
1.
Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953;6(3):619–23.
2.
Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti–CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.
3.
Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemiain first relapse. J Clin Oncol. 2001;19(13):3244–54.
4.
Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.
5.
Giles F, Estey E, O’Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98(10):2095–104.
6.
Tsimberidou AM, Giles FJ, Estey E, O’Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumabozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132(4):398–409.
7.
Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26(25):3679–90.
8.
Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 2008;34(1):49–60.
9.
Petersdorf SH, Kopecky KJ, Slovak ML, et al. A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.
10.
Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77.
11.
Castaigne S, Pautas C, Terré C, et al. Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.
12.
Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–31.
13.
van der Velden VHJ, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197–320.
14.
Farhat H, Reman O, Raffoux E, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: a phase 1/2 study of the Acute Leukemia French Association. Am J Hematol. 2012;87(1):62–5.
15.
Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620–7.
16.
Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IR study [abstract]. Blood. (ASH Annual Meeting Abstracts) 2011;118(21):37–8.
Metadaten
Titel
Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions
verfasst von
Spyridon Dimitrios Chondropoulos, MD
Annaliza Delastic, MD
Alexandros Spyridonidis, MD
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0121-9

Weitere Artikel der Ausgabe 4/2013

ASCO annual meeting 2013: head and neck cancer

  • short review

ASCO 2013—treatment of metastatic melanoma: is it still a story of success?

  • short review

Recent developments in the palliative treatment of breast cancer: ASCO 2013

  • special report

ASCO 2013: news in early-stage and advanced breast cancer

  • short review

Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013

  • short review

The contribution of antibodies to targeted cancer therapy

  • short review